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Prostate cancer is the second leading cause of cancer-related death. The androgen deprivation therapy is the standard treatment
for advanced stages. Unfortunately, virtually all tumors become resistant to androgen withdrawal. The progression to castration-
resistance is not fully understood, although a recent paper has suggested translationally controlled tumor protein to be implicated
in the process. The present study was designed to investigate the role of this protein in prostate cancer, focusing on the correlation
between its expression level with tumor differentiation and response to treatment. We retrieved 292 prostatic cancer specimens; of
these 153 had been treated only by radical prostatectomy and 139 had undergone radical prostatectomy after neoadjuvant treatment
with combined androgen blockade therapy. Non-neoplastic controls were represented by 102 prostatic peripheral zone specimens.
In untreated patients, the expression of the protein, evaluated by RT-qPCR and immunohistochemistry, was significantly higher
in tumor specimens than in non-neoplastic control, increasing as Gleason pattern and score progressed. In treated prostates, the
staining was correlated with the response to treatment. An association between protein expression and themain clinicopathological
factors involved in prostate cancer aggressiveness was identified. These findings suggest that the protein may be a promising
prognostic factor and a target for therapy.
1. Introduction
Prostate cancer (PC) is the most commonly diagnosed
male malignancy and the second leading cause of cancer-
related death [1]. The disease course of PC is highly vari-
able [2]. Most of the tumors develop slowly while others
progress rapidly to life-threatening metastatic disease [3].
Organ confined PC is curable by surgery and radiation
therapy and the prognosis for these patients is excellent [4].
The combined androgen blockade (CAB) is the standard
treatment for inoperable patients with advanced-stage PC
(regional lymph node involvement or metastasis) and for
patients who underwent radiation therapy only [5, 6] since
it inhibits androgen production in the testis with either
chemical or surgical castration and blocks androgen receptor
with an antiandrogen drug. It has been recently demon-
strated that early adjuvant CAB delays the progression of
clinical disease in patients with positive node on histology
[7, 8]. Unfortunately, virtually all tumors become resistant
to androgen withdrawal and develop into castrate-resistant
PC (CRPC), which is associated with high morbidity and
mortality [9]. The progression to CRPC is a process not
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fully understood [10]. It is well known that androgens are
required for normal growth and functioning of the prostate
gland by binding androgen receptors (AR) [11]. AR can
modulate gene expression directly by interactingwith specific
elements in the regulatory regions of target genes or indirectly
by activating various growth factor signaling pathways [12].
Most metastatic CRPC show mutations, amplifications, and
deletions of the AR gene as well as conformational changes of
theARprotein and sensitivity to growth factors and cytokines
[13]. This leads to activation of AR without androgen [14].
An effective treatment for these patients is not yet available
though a new drug (i.e., abiraterone acetate) seems to be
promising [15]. Additional therapeutic strategies targeting
molecular mechanisms-mediating resistance are required,
either to delay or to prevent the emergence of the castration
resistant phenotype [16].The translationally controlled tumor
protein (TCTP) is a protein highly expressed in mammals
and in a wide range of other organisms. The conservation of
TCTP-converging network through phylogeny underscores
its relevance [17]. All the processes regulated by the protein,
including promoting cell growth, activating components of
the mTOR pathway, inhibiting BOX homodimerization and
apoptosis, antagonizing p53, and being overexpressed in
tumors in respect to the normal counterpart, may converge
to a limited set of key events that control stemness pluripo-
tency, tumor reversion, cell fate determination, and ulti-
mately tumorigenesis [17]. Therefore, TCTP combines both
a tumor suppressive and an oncogenic activity that results
in a context-dependent cancer phenotype, representing a
check point and a switch necessary for cellular reprogram-
ming [17]. We have previously demonstrated the presence
of both TCTP mRNA and protein in prostatic tissue, in
prostate cancer cell lines and in the prostatic fluid [18],
suggesting specific roles for the protein such as apoptosis
and control of sperm functions. Recent studies have pro-
posed TCTP as an androgen-regulated gene implicated in
PC, providing preclinical proof-of-principle that combining
antisense oligonucleotide-mediated TCTP knockdown with
castration and/or docetaxel therapy could serve as a novel
strategy to treat CRPC [9, 19]. However, it is not currently
known whether there is a correlation between the different
histological grades of PC and TCTP expression or whether
the protein is expressed in preinvasive lesions as high-grade
prostatic intraepithelial neoplasia (HGPIN). Therefore, the
present study was designed to investigate TCTP expression
in prostate carcinoma, focusing on the correlation between
protein/gene expression level and tumor differentiation. Fur-
thermore, TCTP expression was also studied in neoplastic
tissue after androgen deprivation to obtainmore information
on the hormonal regulation of this protein.
2. Materials and Methods
2.1. Patients. Ethics approval for this study was obtained
from the Institutional Review Board at the University of
Siena (Italy). Informed written consent was gained from
the patients and all specimens were handled and made
anonymous. We retrieved from the archives of Siena Uni-
versity Hospital (Siena, Italy) prostate needle biopsies and
the corresponding radical prostatectomy of 292 patients who
had undergone surgery for PC between January 1999 and
December 2003. Of these, 153 patients had been treated only
by radical prostatectomy and 139 had undergone radical
prostatectomy after neoadjuvant treatment with androgen-
deprivation therapy. Non-neoplastic controls were repre-
sented by 102 prostatic peripheral zone specimens of patients
who underwent cystoprostatectomy for bladder cancer but
with no tumor in prostate gland.Themean age of the patients
at the time of surgery was 69 years (range: 55 to 79 years).
The following biochemical and pathological parameters were
also recorded: total prostatic specific antigen (tPSA), Gleason
score (in both needle biopsies and surgical specimens for
untreated patients, and only in needle biopsies for treated
patients), surgical margins infiltration, extraprostatic exten-
sion, seminal vesicles invasion, lymph node metastasis, and
TNM staging system (based on the AJCC Cancer Staging
Manual, Seventh Edition, 2010, Springer New York, Inc.).The
clinicopathological features of the 292 patients are summa-
rized in Table 1.
2.2. Histology. Core needle biopsies and surgical specimens
had been fixed in 10% buffered formalin and embedded in
paraffin. From each block, 4 𝜇m thick sections had been
cut and stained with haematoxylin and eosin (H&E). All
the slides were reviewed by three expert uropathologists
(MTdV, FC, and CC), who subsequently met to obtain a
consensus diagnosis. Tumor grading was established accord-
ing to the updated Gleason grading system in each sample
[20, 21]. Representative tumor sections were then classified
as low grade when the combined Gleason score (primary
plus secondary pattern) was ≤7 and as high grade when
the combined Gleason score was ≥8. Foci of HGPIN were
also identified, when present in peritumoral areas. Treated
adenocarcinoma patients were classified as good, moderate,
or poor responders on the basis of the changes in the
morphological parameters suggested by Montironi et al.
(nuclear enlargement, prominent nucleoli, cell cytoplasm
vacuolization, acinar shrinkage, isolated infiltrating tumor
cells, difficulty in recognizing prostate cancer patterns, and
amount of interstitial tissue stroma) [22].
2.3. RT-qPCR for TCTP Expression. The expression of TCTP
was evaluated in non-neoplastic and neoplastic prostate
cancers. In particular, neoplastic samples were representative
of different Gleason pattern (Gleason patterns 3–5) and
score and of different response to treatment (poor, moderate,
and good responder patients). Tumor cells corresponding
to different Gleason pattern were isolated by laser capture
microdissection on H&E-stained sections (4-5𝜇m thick)
from formalin-fixed paraffin-embedded tissues, using a laser
capture microdissector (Arcturus, MWG, Florence, Italy).
Microdissected cells were transferred to a Capsure transfer
film, containing 200𝜇L of Trizol (Invitrogen, CA). RNA
was then extracted following manufacturer’s instructions.
Reverse transcription was carried out using the Quantitect
Reverse transcription Kit (Qiagen, CA). For each RNA
specimen, a negative control was prepared by omitting the
reverse transcriptase. TCTP expression was analyzed both in
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Table 1: Main characteristics of the patients included in this study. Univariate descriptive statistics (including frequencies and percentages)
of each qualitative clinical parameter in relation to the two TCTP protein expression levels is shown with the relative 𝑃 value. A statistically
significant association between TCTP protein expression and the main prognostic factors involved in PC aggressiveness is detected.
Variable Group 𝑁 TCTP protein expression 𝑃 value
High Low
Preoperative PSA
<4 6 (2%) 1 (0.8%) 5 (3.1%)
<0.054–10 95 (32.5%) 27 (20.6%) 68 (42.2%)
>10 191 (65.5%) 103 (78.6%) 88 (54.7%)
Surgical margins infiltration Present 162 (55.5%) 91 (69.5%) 71 (44.1%) <0.001
Absent 130 (44.5%) 40 (30.5%) 90 (55.9%)
Extraprostatic extension Present 129 (44.2%) 91 (69.5%) 38 (23.6%) <0.001
Absent 163 (55.8%) 40 (30.5%) 123 (76.4%)
Seminal vesicles invasion Present 49 (16.8%) 40 (30.5%) 9 (5.6%) <0.001
Absent 243 (83.2%) 91 (69.5%) 152 (94.4%)
Lymph node metastasis Present 34 (11.6%) 33 (25.2%) 1 (0.6%) <0.001
Absent 258 (88.4%) 98 (74.8%) 160 (99.4%)
TNM stage
I 29 (9.9%) 0 (0%) 29 (18%)
<0.001II 128 (43.9%) 37 (28.2%) 91 (56.5%)
III 102 (34.9%) 62 (47.4%) 40 (24.9%)
IV 33 (11.3%) 32 (24.4%) 1 (0.6%)
Recurrence Present 120 (41.4%) 114 (87%) 6 (3.7%) <0.001
Absent 172 (58.6%) 17 (13%) 155 (96.3%)
PC: prostatic cancer;𝑁: number of cases and percentage.
non-neoplastic and neoplastic samples by RT-qPCR, using
Taqman probes (Life Sciences, Applied Biosystems, CA)
for TCTP and HPRT as housekeeping gene, according to
the manufacturer’s instructions. Relative quantification was
calculated by the ΔΔCt method [23].
2.4. Immunohistochemistry. The most representative tumor
blocks were selected on the basis of the morphological fea-
tures, and the highest Gleason pattern and score were chosen
both in needle biopsies and in radical prostatectomy for each
nontreated patient. Since Gleason score is not applicable in
treated patients because CAB determines a pronounced sim-
plification of architectural pattern [22], each specimen was
selected depending on the response to treatment (poor, mod-
erate, and good responder patients). Immunohistochemical
stainings were performed on 4 ± 0.5 𝜇m thick sections
of each block employing the Ultravision Detection System
Antipolyvalent HRP (Ultra V Block) (LabVision, Fremont,
CA, USA, Bio-Optica). All the procedures were carried out
automatically by using the Bond-III machine. Slides were
incubated with an anti-TCTP antibody (dilution: 1 : 25) and
the reaction revealed using fucsin (Dako, Milan, Italy) as
chromogen. Sections were weakly counterstained with Har-
ris’ haematoxylin and examined under a light microscope.
Nonimmune serum immunoglobulins were used as negative
control, whereas the positive control was represented by
placental tissue [24].
2.5. Staining Assessment. All of the samples were indepen-
dently evaluated and scored by two investigators (MRA and
BJR), who were blinded to the clinicopathological informa-
tion of the patients. TCTP protein expression levels were
classified semiquantitatively combining the proportion and
intensity of positively stained cells [25–27]. The percentage
of positive-staining tumor cells was scored as follows: 1 (<5%
positive cells), 2 (5–50% positive cell), and 3 (>50% positive
cells) [25–27]. Staining intensity was scored as follows: 1
(weak or not detectable staining), 2 (moderate staining), and
3 (strong staining) [25–27]. Three different fields (at least
100 cells/field) were evaluated at ×200 magnification. In PC
samples TCTP protein expression level was evaluated and
defined only in neoplastic cells. The sum of the staining
intensity score and the percentage score was used to define
the TCTP protein expression level, low: 0–2; high: 3-4. The
agreement between the two pathologist was about 90%.
Cases with discrepancies were reviewed and discussed to
reach the 100% of concordance. In core needle biopsies
and in untreated radical prostatectomies, staining assessment
was performed separately in the two patterns (i.e., 3 and
4 in Gleason score 7, and 4 and 5 in Gleason score 9).
In treated radical prostatectomies, TCTP expression was
evaluated in comparison to the extent of histological response
to treatment.
2.6. Statistical Analysis. Descriptive statistics was computed,
including frequency count, minimum, maximum, mean, and
standard deviation for quantitative variables and frequency
count and percentage for qualitative variables.
The Kolmogorov-Smirnov test was applied to verify
normal distribution of quantitative variables age and PSA.
When normality was assessed, one-way analysis of variance
(ANOVA) was used to compare the two TCTP levels, with
post hoc test of Bonferroni for pairwise comparisons. For








































Figure 1: Relative expression of TCTP by RT-qPCR in tumors of different pattern in respect to normal control. In untreated patients, higher
expression is observed in cancer, in respect to non-neoplastic control, with an increase as tumor grade progresses (a) (𝑡-test, 𝑃 < 0.05). In
treated patients, we found that the more the treatment is effective, the less the expression level of TCTP is, which is almost comparable to
non-neoplastic control in GR (b) (GR: good responders; MR: moderate responders; PR: poor responders) (𝑡-test, 𝑃 < 0.05). The graphs are
representative of three different experiments. Error bars indicate standard deviation.
nonnormal data we otherwise used the nonparametric tests
of Kruskal-Wallis and the Dunn post hoc test.
TheKendall rank correlation coefficient, 𝜏, was computed
to evaluate the correlation between TCTP levels and all the
at-least-ordinal variables.
When computable, the Fisher exact test was applied to
contingency tables to evaluate the association between the
frequency distributions of TCTP levels and each qualitative
variable. We alternatively used the classic 𝜒2 test.
The prognostic power of TCTP, with relation to the
disease-free survival (DFS) time, was investigated by using
the Cox proportional hazards model.Themultivariate model
was designed in a stepwise manner, by including at any
successive step only the prognostic factors (covariates) that
could be associatedwith survivalwith a statistical significance
greater than 95% (𝑃 < 0.05). The stepwise method allows
univariate survival analysis to be also evaluated at step 0.
The hazard ratio (HR) and its 95% confidence interval were
computed for each prognostic factor, for both univariate
and multivariate analyses. HR represents the odds that an
individual in the group with the highest risk reaches the
endpoint first. Finally, the Kaplan-Meier DFS curves for
the two TCTP levels were drawn and statistically compared
through the log rank test.
In each group, the difference in TCTP expression between
needle biopsy and radical prostatectomy was evaluated.
Results were considered statistically significant when they
exceeded the 95% probability level (𝑃 < 0.05).
3. Results
3.1. TCTP mRNA in Untreated and Treated PC. The expres-
sion of TCTP in non-neoplastic and neoplastic prostate
samples was evaluated by RT-qPCR. Relative quantifica-
tion indicated that the expression of TCTP is significantly
higher in tumor specimens than in non-neoplastic control,
increasing as Gleason pattern (Figure 1(a)) andGleason score
progressed (𝑡-test, 𝑃 < 0.05). In patients treated with CAB,
TCTP expression is correlated to response to therapy, being
higher in poor responders and lower in good responders
(Figure 1(b)) (𝑡-test, 𝑃 < 0.05).
3.2. TCTP Protein Expression in Untreated and Treated PC.
Among the non-neoplastic specimens, 78 showed atrophy
and 24 atrophy plus chronic inflammation. A low TCTP
expression was detected in the cytoplasm of the epithelial
cells, mainly located in the apical portion and blebs, whereas
the basal layer cells showed a strong positivity. Among the
153 untreated PC, 57 were Gleason score 6, 52 Gleason score
7, 25 Gleason score 8, 17 Gleason score 9, and 2 Gleason score
10. For the Gleason scores 7 and 9, TCTP protein expression
was also evaluated separately in the two patterns (i.e., 3 and
4 for Gleason score 7 and 4 and 5 for Gleason score 9). A
correlation betweenTCTP immunostaining andGleasonpat-
tern and score was observed. TCTP protein expression was
higher in high Gleason pattern (i.e., 4 and 5) in comparison
to lowGleason pattern (i.e., 3) (𝑃 < 0.04) (Figures 2(a)–2(c)).
As far as Gleason score is concerned, TCTP immunostaining
was significantly lower in Gleason score 6 PC (𝑃 < 0.001)
and stronger in Gleason score 8 to 10 PC (𝑃 < 0.001)
(Table 2(a)). In Gleason score 7 PC an intratumoral hetero-
geneity was observed, with a higher TCTP protein expression
in Gleason pattern 4 than in Gleason pattern 3. The stromal
cells both in non-neoplastic and in neoplastic specimens
showed a mild staining. Strong staining was observed in
cancer-associated HGPIN (Figure 2(d)). No differences in
TCTP protein expression were observed between the needle
biopsies and the corresponding radical prostatectomy of the
same Gleason pattern. In treated prostates, 48 were good
responders, 40 were moderate responders, and 51 were poor
responders. The intensity of TCTP immunostaining was
higher in poor responders and lower in good responders
(Table 2(b) and Figures 3(a)-3(b)) (Kendall’s 𝜏: 0.773, 𝑃 <
0.001).
3.3. Association of TCTP Protein Expression with the Prog-
nostic Factors of Prostatic Carcinoma. We investigated the
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Figure 2: TCTP protein expression in untreated patients. TCTP staining increases as Gleason pattern progresses from Gleason pattern 3 (a)
to Gleason pattern 4 (b) to 5 (c); in the latter isolated neoplastic cells strongly express the protein (𝜒2-test, 𝑃 < 0.001). High positivity is also
present in associated-cancer HGPIN ((d), arrow) in respect to the non-neoplastic tissue. (Original Magnification, O.M.: (a)–(d), 10x).
Table 2: (a) Immunohistochemical results in untreated patients.The
association between TCTP protein expression and Gleason score is
shown, with higher TCTP protein expression in high Gleason score
samples (Gleason score ≥8) (𝑃 < 0.001). (b) Immunohistochemical
results in treated patients. The association between TCTP protein
expression and response to treatment is shown, with lower TCTP
protein expression in good responder patients (𝑃 < 0.001).
(a)
Gleason score 𝑁 % TCTP protein expression
High Low
6 57 37.3 4 (7%) 53 (93%)
7 52 34 28 (53.8%) 24 (46.1%)
8 25 16.3 24 (96%) 1 (4%)
9 17 11.1 17 (100%) 0 (0%)
10 2 1.3 2 (100%) 0 (0%)
(b)
Response to treatment 𝑁 % TCTP protein expressionHigh Low
Poor 51 36.7 50 (98%) 1 (2%)
Moderate 40 28.8 24 (60%) 16 (40%)
Good 48 34.5 2 (4.2%) 46 (95.8%)
association between TCTP protein expression status and the
well-recognized prognostic factors of PC. The intensity of
TCTP was directly correlated with higher preoperative PSA
(𝑃 < 0.05), stage (𝑃 < 0.001) and Gleason score (𝑃 < 0.001),
surgical margins infiltration (𝑃 < 0.001), extraprostatic
extension (𝑃 < 0.001), seminal vesicles invasion (𝑃 < 0.001),
and lymph node metastasis (𝑃 < 0.001). On the contrary, no
correlation has been identified betweenTCTP expression and
the age of the patients (𝑃 = 0.99) (Figures 4(a)–4(f)).
3.4. Disease-Free Survival Analysis. TheKaplan-Meier curves
of TCPC protein expression are shown in Figure 5. DFS was
significantly different between the groups with high and low
TCTP expression (log rank test, 𝑃 < 0.001). In particular, the
group with the higher TCTP protein expression had a shorter
DFS (mean = 64 months; 95% CI = 57–70 months) when
compared to the group showing the lower TCTP protein
expression (mean = 178 months; 95% CI = 171–185 months).
Univariate Cox analysis showed that all the prognostic factors
known to be involved in PC are highly statistically correlated
with DFS (𝑃 < 0.001) except for the age (𝑃 = 0.73). In
addition, we found no differences in DFS between the treated
and the untreated patients (𝑃 = 0.32), thus confirming that
the neoadjuvant treatment does not affect patients’ prognosis.
Stepwise multivariate analysis enrolling the above mentioned
parameters and the TCTP protein staining demonstrated that
TCTP was not an independent prognosticator but influences
patients’ outcome (HR = 49.7, CI 95% = 19.4–127.1 for high
TCTP staining).
4. Discussion
TCTP is a multifaceted protein which has been implicated
in a number of key cellular processes, both physiologic
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(a) (b)
Figure 3: TCTP protein expression in treated patients. The intensity of immunostaining is absent or low in good responders (a) and high in
























































































Figure 4: Association of TCTP protein expression with the main prognostic factors involved in PC aggressiveness. Univariate analysis by
Fisher exact test and/or 𝜒2-test shows that TCTP protein expression level is significantly associated with higher preoperative PSA (a) (𝑃 <
0.05), surgical margins infiltration (b) (𝑃 < 0.001), extraprostatic extension (c) (𝑃 < 0.001), seminal vesicles invasion (d) (𝑃 < 0.001), lymph
node metastasis (𝑃 < 0.001) (e), and higher TNM stage (f).
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Figure 5: Kaplan-Meier curves of TCTP protein expression levels.
Disease free survival was significantly different between the groups
with high and low TCTP protein expression (log rank test, 𝑃 <
0.001). The group with the higher TCTP protein expression has a
shorter disease free survival (mean = 64 months) when compared
to the group with the lower TCTP protein expression (mean = 178
months).
and pathologic, such as development, immune response, cell
cycle, cell proliferation and growth, cell division, cytoskeleton
activity, protein synthesis, and calcium binding [28, 29].
Recent studies have shown the contribution of TCTP in cell
growth and proliferation of prostate cancer, suggesting TCTP
as a novel possible therapeutic target in the treatment of
castration-resistant PC [9, 19]. We have previously demon-
strated TCTP expression in the human prostate cancer cell
lines, LNCaP and PC-3, and in the non-neoplastic human
prostate epithelial cells, PwR-1E [18] as well as in prostatic
tissues from patient who underwent adenomectomy for
benign prostatic hyperplasia. In the present study we have
confirmed our previous data on a larger series of primary
tumors by RT-qPCR and immunohistochemistry.
To the best of our knowledge, no previous papers have
analyzed the correlation between TCTP expression and
tumor grading as well as the influence that CAB may exert
on the expression of this protein in PC. In our study we show
that inHGPIN adjacent to adenocarcinomaTCTP expression
was always strong, both in treated and untreated prostate.The
overexpression of this protein in the initial phases of neo-
plastic transformationmay support the hypothesis that TCTP
could exert a role in tumorigenesis. In untreated prostate, the
most striking evidence is that TCTP expression significantly
correlates with tumor grading, being high in Gleason score
≥8 PC and low in Gleason score ≤7 PC, indicating a possible
correlation with cell differentiation. Interestingly, in Gleason
score 7, TCTP expression shows areas of different distribution
and intensity, being stronger in Gleason pattern 4 than in
Gleason pattern 3. This underlines the heterogeneity of PC
and may explain why Gleason score 7 prostatic carcinomas
with the same stage, but with different extension of Gleason
pattern 4, may have different clinical behaviors. One should
speculate that the aggressiveness of the tumor may really
depend on this parameter. In untreated patients we do
not identify differences in the expression of TCTP between
needle biopsies and the corresponding radical prostatectomy,
in cases with the same Gleason pattern and score; therefore
TCTP may represent a promising tool to be used in initial
needle biopsies to predict the biological aggressiveness of the
tumors and to select an optimal therapeutic treatment for
each patient [19]. In treated patients we find a correlation
between the intensity and expression of TCTP in cancer
and the response to CAB. This may explain the initial good
effect of hormonal treatment andmay confirmprevious study
demonstrating the utility of early adjuvant CAB in advanced
disease [7]. However, we do not knowwhether good response
to treatmentmay be related to TCTP’s androgen regulation or
to sensitivity to androgen withdrawal and if other androgen
related genes may behave in a similar manner.
Univariate analysis shows that Gleason score, TNM stage,
and TCTP expression have a statistically significant correla-
tion with DFS. Among these parameters, multivariate analy-
sis identifies Gleason score and TCTP protein expression as
the best predictors, when combined, of aggressiveness of PC.
5. Conclusions
Collectively, our data demonstrate that, in PC, TCTP expres-
sion is directly correlated with tumor differentiation and
with the main clinicopathological factors involved in PC
aggressiveness. The assessment of TCTP staining in needle
biopsies from PC patients may be of help in evaluating the
more appropriate therapeutic strategies.
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